MTEX MANNATECH INC
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1056358 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.6%
TTM net income YoY74.3%
TTM EPS YoY64.0%
Revenue 3-yr CAGR-8.3%
Net income 3-yr CAGR—
Margins
Gross margin75.7%
Operating margin0.9%
Net margin-0.4%
FCF margin-0.6%
EBITDA margin1.9%
Returns
ROE-7.0%
ROA-1.4%
ROIC (approx.)17.8%
Asset turnover3.33x
Leverage & solvency
Liabilities / assets81.3%
Debt / equity0.53x
Current ratio1.18x
Interest coverage2.00x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.87M | $26.65M | $24.92M | $26.64M | $29.16M | $25.68M | $26.56M | $29.01M |
| Cost of revenue | $6.29M | $6.16M | $6.06M | $6.58M | $6.89M | $6.78M | $6.83M | $5.64M |
| Gross profit | $18.58M | $20.49M | $18.86M | $20.05M | $22.27M | $18.90M | $19.74M | $23.36M |
| SG&A expense | $8.70M | $8.98M | $9.28M | $9.79M | $9.07M | $10.78M | $10.02M | $10.43M |
| Operating income | $272,000 | $998,000 | -$180,000 | -$157,000 | $2.01M | -$1.44M | -$833,000 | $864,000 |
| Interest expense | $119,000 | $117,000 | $104,000 | $127,000 | $104,000 | $102,000 | $73,000 | $83,000 |
| Pretax income | -$1.95M | $1.17M | $1.11M | $210,000 | $2.51M | -$4.29M | -$1.32M | $2.88M |
| Income tax | -$10.86M | $150,000 | $161,000 | $11.51M | $590,000 | $23,000 | $206,000 | $614,000 |
| Net income | $8.90M | $1.01M | $950,000 | -$11.29M | $1.92M | -$4.31M | -$1.53M | $2.26M |
| EBITDA | $518,000 | $1.26M | $81,000 | $103,000 | $2.27M | -$1.17M | -$540,000 | $1.22M |
| EPS (basic) | 4.61 | 0.53 | 0.49 | — | 1.01 | -2.27 | -0.80 | — |
| EPS (diluted) | 4.61 | 0.53 | 0.49 | — | 1.01 | -2.27 | -0.80 | — |
| Weighted avg. shares (diluted) | 1.93M | 1.93M | 1.93M | — | 1.90M | 1.90M | 1.90M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | -$73,000 | -$83,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $5.42M | $6.03M | $7.01M | $6.18M | $7.14M | — | $9.32M | $11.40M |
| Receivables | $1,000 | $137,000 | $10,000 | $1,000 | $38,000 | — | $102,000 | $19,000 |
| Inventory | $9.57M | $9.59M | $9.67M | $10.12M | $11.13M | — | $11.82M | $10.40M |
| Current assets | $19.79M | $19.41M | $21.20M | $20.58M | $22.09M | — | $26.55M | $26.12M |
| PP&E, net | $2.64M | $2.75M | — | $3.14M | $3.23M | — | — | $2.71M |
| Intangibles | $237,000 | $237,000 | $237,000 | $237,000 | $237,000 | — | — | $237,000 |
| Total assets | $27.90M | $27.47M | $29.88M | $29.99M | $33.92M | — | $36.67M | $36.06M |
| Current liabilities | $16.80M | $16.86M | $19.47M | $18.73M | $19.50M | — | $22.58M | $20.90M |
| Long-term debt | $2.75M | $2.75M | $2.75M | $2.75M | $2.90M | — | — | — |
| Total debt | $2.75M | $2.75M | $2.75M | $2.75M | $2.90M | — | — | — |
| Total liabilities | $22.70M | $32.44M | $35.44M | $35.22M | $26.97M | — | $29.08M | $27.44M |
| Shareholders' equity | $5.20M | -$4.97M | -$5.55M | -$5.22M | $6.95M | $5.96M | $7.58M | $8.61M |
| Net debt | -$2.67M | -$3.28M | -$4.26M | -$3.44M | -$4.24M | — | — | — |
| Shares outstanding | 1.93M | 1.93M | 1.93M | 1.90M | 1.90M | — | 1.90M | 1.88M |
| Cash flow statement | ||||||||
| Operating cash flow | -$249,000 | -$792,000 | $1.13M | -$289,000 | $2.41M | -$3.72M | -$1.37M | -$219,000 |
| Capital expenditure | $131,000 | $10,000 | $129,000 | $174,000 | $548,000 | $142,000 | $489,000 | -$106,000 |
| Free cash flow | -$380,000 | -$802,000 | $997,000 | -$463,000 | $1.86M | -$3.86M | -$1.86M | -$113,000 |
| Investing cash flow | -$131,000 | -$10,000 | -$129,000 | -$174,000 | -$548,000 | -$142,000 | -$489,000 | $118,000 |
| Financing cash flow | -$148,000 | $228,000 | -$126,000 | -$242,000 | -$73,000 | -$80,000 | -$166,000 | -$905,000 |
| Depreciation & amortization | $246,000 | $259,000 | $261,000 | $260,000 | $261,000 | $278,000 | $293,000 | $360,000 |
| Stock-based compensation | $26,000 | $54,000 | $274,000 | $32,000 | $38,000 | $158,000 | $263,000 | $22,000 |
| Dividends paid | — | — | — | — | — | — | — | $0 |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 73 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.